# CDP323 Biomarker Study

> **NCT00726648** · PHASE1,PHASE2 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 71 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **DRUG:** CDP323
- **DRUG:** CDP323
- **DRUG:** CDP323
- **DRUG:** CDP323
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00726648
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2011-09-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00726648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00726648, "CDP323 Biomarker Study". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00726648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*